Science is producing assets faster than capital markets can finance them.

India is creating world-class scientific IP, clinical datasets, and development programs. The problem is not a shortage of innovation; it is the absence of a mechanism to finance intangible scientific assets independently of the corporate wrapper.

$195.3B

India Bioeconomy 2030 Target

-48%

Private Cap Contraction (YoY)
LEGAL ARCHITECTURE

The SEBI Precedent Pattern

We are not inventing new law. We are applying existing, battle-tested securitisation frameworks to a new asset class. Just as real estate and infrastructure were securitised into REITs and InvITs, scientific IP can be isolated into cash-flow generating structures.

Real Estate
REITs
Infrastructure
InvITs
Scientific IP & Datasets
SARs (Scientific Asset Receipts)
TRADITIONAL MODEL

Equity Investment (Corporate Wrapper)

Dilutive corporate equity with bundled management, operational, and scientific risk. Capital remains illiquid for over a decade.
NEW SECURITISED FRAMEWORK

Scientific Asset Receipts (SARs)

Bankruptcy-remote SPVs hold isolated IP rights. Yield and milestone royalties flow directly to fractional receipt holders without corporate equity dilution.
THE SARs MECHANISM

How Scientific Asset Receipts Work

A three-step execution pipeline decoupling scientific innovation from balance sheet debt and operational exposure.

STEP 01

Asset Origination

Research institutions, labs, or biotech firms originate patents, clinical datasets, or licensing rights.
STEP 02

SPV Isolation

Intangible assets are transferred to a Trustee-held, bankruptcy-remote SPV, ring-fenced from originator liabilities.
STEP 03

Capital Issuance

SPV issues fractional SARs to qualified investors, distributing milestone royalty yields and secondary liquidity.
SOLVING THE PRICING BOTTLENECK

How Scientific Asset Receipts Work

A three-step execution pipeline decoupling scientific innovation from balance sheet debt and operational exposure.

Representational Intelligence

Translates highly complex, raw biological evidence and clinical trial data into standardized, digestible financial disclosure formats for capital allocators.

Pricing Intelligence

Synthesizes global literature, patent landscapes, and clinical readouts into continuously updated, probability-based risk pricing models.

Community Intelligence

Aggregates qualitative inputs from domain experts and researchers, converting human consensus into quantitative signals to audit the algorithms.
BY INVITATION ONLY

Request a Seat at The Scientific Capital Table

Participation is strictly limited to 40 primary decision-makers across Sovereign Funds, Family Offices, Biopharma CEOs, Market Intermediaries, and Policy Leaders.

Request an Invitation

BioVergence × Nishith Desai Associates

PropositionThe RoomAgendaSingapore
© 2026 BioVergence × Nishith Desai Associates.
Signal → Structure → Market → Intelligence → Capital